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a  b  s  t  r a  c t
TGF1 is a major fibrotic  factor  and  its actions involve  induction  of epithelial cell  death,  together with
the  stimulation and  transdifferentiation  of fibroblasts  into  collagen- and  fibronectin-secreting  myo-
fibroblasts.  These actions of TGF1 are also  consistent  with  a pro-metastatic  role,  by  aiding  epithelial
cell  escape through  mesenchymal  tissues.  Recently  IGFBP-5  has  been described as a  pro-fibrotic (pro-
metastatic?)  agent  and the  aim of this  study was to compare  and  contrast the  actions of IGFBP-5  with
TGF1.  We  used NMuMG  cells  and  cloned stable  epithelial  and mesenchymal  lines  from  the  parent  cells.
TGF1  induced  apoptosis  and/or EMT in the  epithelial cells,  whereas  it enhanced  mesenchymal  cell
survival  and  migration.  IGFBP-5, in contrast, enhanced both  cell–cell  and  cell–ECM  adhesion  and also
improved  wound closure in epithelial cells  whereas,  in mesenchymal  cells,  IGFBP-5  decreased  adhesion
and migration.  Furthermore,  IGFBP-5  was able to antagonise  the actions of TGF1.  In  a co-culture model
simulating  epithelial–mesenchymal  boundaries,  IGFBP-5  was  able to antagonise  the  disruptive  trans-
gressions  induced by  TGF1.  Overall, these  findings  suggest  that IGFBP-5  is  important in  maintaining
epithelial–mesenchymal  boundaries  and thus  may  limit  metastasis  and  fibrosis  by  inducing  an  orderly
repair  mechanism, very  distinct from  the  fibrotic  disruption  induced by  TGF1.  A  role  for IGFBP-5  in
the  inhibition  of metastasis  is supported  by  immunohistochemical  studies  of breast  cancer microarrays,
where  we show that  elevated IGFBP-5  expression is  associated  with  increased disease-free  survival.
© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Tissue boundaries must be formed and maintained, despite
a range of traumatic insults, such as the wound healing pro-
cess, which can ultimately manifest itself in  a  variety of chronic
fibrotic disorders, where healing remains unresolved (Wynn and
Ramalingam, 2012) or metastasis, where epithelial cells cross mes-
enchymal tissues and endothelial barriers.
The principal agent driving EMT  is TGF-1 (Margadant and
Sonnenberg, 2010). TGF1 induces apoptosis in epithelial cells but
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can also induce EMT  in  the surviving cells. Thus, although TGF1
is thought to be protective in  the early stages of tumour formation
(pro-apoptotic) it is  a poor prognostic factor during metastatic dis-
ease (pro-EMT) (Roberts and Wakefield, 2003; Siegel and Massague,
2003). By increasing collagen and fibronectin production from
fibroblasts and inducing their trans-differentiation into myo-
fibroblasts, TGF-1  acts to  disrupt the epithelial–mesenchymal
boundary, generating a  fibrotic response which impairs wound
healing (Nakerakanti and Trojanowska, 2012). Insulin-like growth
factor binding protein-5 (IGFBP-5) is  increased in fibrotic disorders
(Feghali and Wright, 1999; Zuo et al., 2002) and induces fibrotic
responses similar to TGF-1 (Yasuoka et al., 2006a, 2006b, 2008).
However, we  believe that IGFBP-5 and TGF-1 serve very different
functions. For example, we have demonstrated that IGFBP-5
increases epithelial cell adhesion to  the ECM, whilst simulta-
neously inhibiting migration by maintaining E-cadherin expression
(Sureshbabu et al., 2012). These responses to IGFBP-5 would be
anticipated to reduce, rather than increase, metastatic potential
and to  limit fibrotic responses to the mesenchymal compartment by
maintaining an effective epithelial barrier. Paradoxically, increased
IGFBP-5 expression has been associated with poor prognosis
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Fig. 1. Characterisation of NMuMG  epithelial and mesenchymal clones. Panel A: Bright field images, demonstrating the difference in phenotype of the cells. Bar =  100  m.
Panel  B: expression of F-actin, at  the plasma membrane in epithelial clones and as stress fibres in  the mesenchymal clones. Bar represents 50 m. Panel C: Epithelial cells
exclusively express E-cadherin whereas mesenchymal cells do  not. Bar represents 100 m. Panel D: Mesenchymal cells express collagen whereas epithelial cells do not.
Bar  represents 25 m. Panel E: Expression of fibronectin is  greatly increased in mesenchymal cells. Bar represents 20 m. Panel F:  When co-cultured, the cells organise
into  epithelial colonies surrounded by mesenchymal cells. Bar represents 100 m. Panel G:  In 3D culture, epithelial cells form regular spheroids (visualised via e-cadherin
expression) whereas mesenchymal cells form elongated structures expressing fibronectin. Finally, when co-cultured in 3D, spheroids are connected to each other by duct-like
structures. Bar represents 100 m.
during metastasis (Hou et al., 2009; Huynh, 1998; McGuire et al.,
1994; Mita et al., 2007; Pekonen et al., 1992). Rather than inducing
metastasis however, we believe that IGFBP-5 secretion might
actually reflect a  host response to  limit tumour escape.
To test this hypothesis, we compared the actions of TGF1  and
IGFBP-5, exploring their individual roles in the maintenance of the
epithelial–mesenchymal boundary. We took advantage of a  nor-
mal  mouse mammary cell line (NMuMG), where epithelial cells
exhibit both apoptosis and EMT  in  response to TGF1. Furthermore,
this cell line has previously been used to  generate both epithelial
and mesenchymal clones (Maeda et al., 2005) which allowed the
actions of these growth factors to be examined in different phe-
notypic states of the same cell line. We describe actions of IGFBP-5
which suggest a role as a  natural antagonist of TGF-1 in  the epithe-
lial compartment, which would be anticipated to improve wound
healing responses and to limit metastatic escape of epithelial cells.
We also investigated if  this was clinically relevant by  assessing
the prognostic significance of IGFBP-5 in  a  cohort of human breast
cancer specimens.
2. Results
2.1. Generation of epithelial and mesenchymal clones of NMuMG
cells
Using a limiting-dilution technique, we were able to clone stable
lines which exhibited either epithelial or mesenchymal charac-
teristics (Fig. 1). Epithelial clones were easily identifiable by the
tight colonies formed, whereas there was an absence of such
interaction in  the mesenchymal lines (Fig. 1A). In the epithe-
lial  clones, F-actin was  arranged around the periphery of the
cell, whereas it was evident as stress fibres in  the mesenchymal
clones (Fig. 1B). The differences in  phenotype were confirmed by
demonstrating E-cadherin expression in  the epithelial clones but
not the mesenchymal clones (Fig. 1C), whilst the mesenchymal
clones exhibited staining for collagen (Fig. 1D) and fibronectin
(Fig.  1E), which the epithelial clones did not. When the cells were
co-cultured by seeding as a  mixture, the cells arranged them-
selves with epithelial colonies surrounded by mesenchymal cells
(Fig.  1F). When cultured on matrigel, to encourage 3D growth,
the epithelial clones formed characteristic spheroids, whereas the
mesenchymal clones developed structures more closely resem-
bling ductal or tubular structures (Fig. 1G). When mixed, the
cells organised themselves into spheroids, linked by  mesenchy-
mal  duct-like structures (Fig. 1H). Because the mesenchymal cells
were apparently derived from the original parent cell and the
possibility existed of a mesenchymal-epithelial transition (MET),
which could make interpretation difficult in some of our co-culture
experiments, some studies were also undertaken with a  classic
mesenchymal cell, the 3T3 fibroblast, which does not  undergo MET.
3T3 cells also exhibited abundant collagen expression (see Fig. 6),
which could be used as a  reliable marker for their identification in
culture.
2.2. Responses of NMuMG cells to TGFˇ1, IGF-I and insulin
We  undertook some initial studies to characterise the response
of both epithelial and mesenchymal clones to  TGF1 as well
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Fig. 2. TGF1 induces apoptosis in epithelial cells but survival in mesenchymal cells.
IGF-I  and insulin support survival in both cell  types. Panel A: Cell survival response
to  growth factors in epithelial and mesenchymal clones of NMuMG cells. Cells were
seeded in the presence of 10% serum overnight to allow attachment, after which
the  cells were washed to  remove the serum and cultured in the presence of various
growth factors in 2% FCS DMEM for 2 d. Cells were then fixed, stained with crystal
violet and absorbance values determined at 540 nm. Values are  means ± SEM of 6
observations. **p < 0.01, ***p < 0.001 compared with control cells (ANOVA followed
by  Bonferroni’s test for multiple comparisons). Panel B: TGF1  induces apoptosis
of  NMuMG epithelial clones (dying cells evident as dark, shrunken spheroids but
EMT  is evident in the surviving cells which show little cell–cell interaction). Acting
re-arrangement is evident after TGF1 treatment with stress fibre formation, which
contrasted with the expression of F-actin in the plasma membrane of control cells.
Bar  represents 25 m.  Panel C: TGF1  induces cell death and down-regulation of
E-cadherin expression. Epithelial cells were cultured with TGF1 with or without
BMP-7 for 3 d and then fixed and stained for E-cadherin (green) and DAPI (blue).The
effects of TGF1 were completely abolished by  concurrent treatment with BMP-7, a
TGF1  inhibitor. Bar represents 50 m.(For interpretation of the references to color
in  figure legend, the reader is  referred to  the web version of the  article.)
as  to IGF-I, which acts as a  major survival factor for these
cells. We also used insulin as a  surrogate IGF-I because it is
incapable of interaction with IGFBP-5 and can thus be used to
help distinguish IGF-dependent and IGF-independent effects of
IGFBP-5.
In order to examine the effects of growth factors, the cells were
cultured in low (2%) serum, sufficient to  allow the cells to  adhere
but limiting their survival and proliferative potential. By day 3,  cell
numbers were decreased by  approximately 50% in control wells of
both epithelial and mesenchymal cells. IGF-I and insulin prevented
the decrease in cell numbers of epithelial and mesenchymal clones
(Fig. 2A). In contrast, although TGF1 also inhibited the decrease
in cell numbers of mesenchymal clones, it led to  an even greater
decrease in epithelial cells than in  control wells, resulting in an
80% decrease in epithelial cell numbers.
When we examined the actions of TGF1 on epithelial clones,
it was evident that the surviving cells had undergone a phenotypic
epithelial–mesenchymal transition (EMT) (Fig. 2B) which involved
down-regulation of E-cadherin expression (Fig. 2C), an effect which
could be prevented by the TGF1 antagonist, BMP-7.
These results provided us with confidence that these clones
would be suitable to examine the actions of IGFBP-5, in order to
compare and contrast them with TGF1 in epithelial and mes-
enchymal cell lines.
2.3. Effects of IGFBP-5 on adhesion of epithelial clones
Based upon our previous studies which had demonstrated that
IGFBP-5 could enhance adhesion of MCF-7 epithelial cells to  both
collagen and fibronectin, as well as other provisional matrices
(Sureshbabu et al., 2012), we conducted short-term (30 min) exper-
iments in serum-free conditions. IGFBP-5 potently enhanced the
adhesion of epithelial clones to the substratum and this was  par-
ticularly pronounced for collagen and fibronectin, when compared
with laminin (Fig.  3A  and B).
Epithelial clones survived poorly in  serum-free conditions dur-
ing  prolonged (overnight) culture and this was evident from the
fact that untreated cells showed little or no interaction with each
other or  adhesion to the substratum. Metabolic activity, judged by
WST-1 activity was  also very low (results not shown). In contrast
both insulin and IGF-I stimulated considerable cell–cell adhesion,
generating metabolically-active spheroids (Fig. 3C).  To our surprise,
IGFBP-5, despite having initially induced adhesion to the substra-
tum, also induced the formation of spheroids. Quantification of
spheroid number and size revealed that both IGF-I and insulin
increased spheroid size, whereas IGFBP-5 increased spheroid num-
bers (Fig. 3D).  Intriguingly, when cells were treated with both IGF-I
and IGFBP-5 (in approximately equimolar concentrations), neither
the number or size of spheroids was  increased compared with
controls, suggesting that they neutralised each other. This begs
the question “Which factor inhibits which?” Support for indepen-
dent actions of IGF-I and IGFBP-5 on NMuMG epithelial clones
came from co-incubation of IGFBP-5 and insulin (which do not
interact with each other). This resulted in  the formation of even
larger spheroids. TGF1 completely inhibited the formation of
spheroids. Thus, in  stark contrast to TGF1, IGFBP-5 supported
epithelial cell survival, apparently by driving both cell adhesion
and cell–cell contact. Furthermore, when epithelial cells were cul-
tured in the presence of serum to allow attachment and survival,
IGFBP-5, expressed from an adenoviral construct, was  able to  par-
tially inhibit the apoptotic effects of TGF1 (Fig.  3E).  IGFBP-5
could also limit the epithelial–mesenchymal transition induced
by TGF1. IGFBP-5 had no effect on actin arrangement on its
own, with cells showing the characteristic epithelial expression of
actin around the plasma membrane (Fig. 3F upper panel). In con-
trast, TGF1 induced re-alignment of actin into stress fibres and
led to dramatic elongation and alignment of cells. Although actin
re-arrangement was also evident with the combined treatment
of TGF1 and IGFBP-5, cell alignment and elongation were con-
siderably reduced. However, IGFBP-5 was unable to prevent the
down-regulation of E-cadherin induced by TGF1 (Fig. 3F lower
panel) indicating that  it was, at best, a partial antagonist of  this
action of TGF1.
2.4. Actions of IGFBP-5 on adhesion in mesenchymal cells
When IGFBP-5 was used to treat mesenchymal clones of
NMuMG  cells or 3T3 cells, there was a  remarkable decrease in
cell adhesion to  laminin, fibronectin or  collagen (Fig. 3G and
H) which was  not evident in response to TGF1. The initial
action of IGFBP-5, however, was  to induce mesenchymal cells
to migrate towards each other, again forming small spheroids
(Fig. 3I – arrowheads). These structures did not, however, sur-
vive fixation and washing procedures. Once again, this action
was distinct from that of TGF1, which induced mesenchy-
mal cell survival, characterised by increased cell numbers, cell
elongation and swirling patterns, characteristic of myofibroblast
trans-differentiation (Fig. 3I). When TGF1 and IGFBP-5 were
added together, the effect of IGFBP-5 pre-dominated over the
actions of TGF1 (Fig. 3J).
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Fig. 3. IGFBP-5 enhances adhesion and survival of epithelial cells but decreases adhesion of mesenchymal cells. Panel A: Treatment with IGFBP-5 increases adhesion of
NMuMG  epithelial cells. NMuMG  cells (in 0.1% BSA DMEM) were seeded into 96-well plates coated with laminin, fibronectin or collagen. After 30 min  culture at 37 ◦C, the
plates  were inverted, washed and fixed in 4% paraformaldehyde. They were then stained with crystal violet, photographed and absorbances were determined at 540 nm. Bar
represents 100 m.  Panel B: Quantification of the results of the study shown in Panel A.  Values are means ± SEM of 6 observations. ***p <  0.001 compared with control cells
(ANOVA followed by Bonferroni’s test for multiple comparisons). Panel C: NMuMG  cells were trypsinised and seeded into 96-well plates at 4 ×  105 cells/ml in 0.1% BSA DMEM
along with insulin (10 g/ml), IGF-I (100 ng/ml), IGFBP-5 (10 g/ml), TGF1 (10 ng/ml) or combinations of these. After 24  h  culture at 37 ◦C,  cells were photographed under
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2.5. Mechanism of action of IGFBP-5
In order to assess the role of intracellular signalling in  the actions
of IGFBP-5, we utilised a  variety of kinase inhibitors. The actions
of IGFBP-5 on epithelial spheroid formation were unaffected by
any of the classical kinase inhibitors tested (Fig. 4A) .  In contrast,
the action of TGF1  on epithelial cells was, as expected, blocked
by the inhibitors of the type I receptors ALK4/5/7, A.8301 and
SB431542 (Fig. 4B). TGF1 increased phosphorylation of Smad 2/3,
whereas IGFBP-5 had no effect, either alone or  in  combination with
TGF1 (Fig. 4C) The de-adhesive action of IGFBP-5 on mesenchy-
mal  clones was also unaffected by  any of the kinase inhibitors
tested although the PI3-kinase inhibitor LY294002 also inhibited
cell adhesion alone, so no definitive conclusion could be made about
PI3-kinase and IGFBP-5 (Fig. 4D  and E).
2.6. Effects of IGFBP-5 and TGFˇ1 on wound closure
Effects of IGFBP-5 and TGF1 on wound closure were examined
either alone, or in  combination, using ibidi 2-chamber migra-
tion inserts. TGF1 inhibited epithelial wound closure (Fig. 5A
and C), whereas it enhanced wound closure in mesenchymal cells
(Fig. 5B–D). In contrast, IGFBP-5 enhanced wound closure of epithe-
lial cells, either alone or in combination with TGF1 (Fig. 5A–C),
but significantly antagonised the effect of TGF1 in mesenchymal
clones, although it had no effect alone.
2.7. Effects of IGFBP-5 and TGFˇ1 on maintenance of
epithelial–mesenchymal boundaries
We  next examined the ability of IGFBP-5 and TGF1 to influ-
ence boundary formation between epithelial NMuMG  clones and
3T3 fibroblasts. 3T3 fibroblasts were used to  avoid potential
MET  transformations that might be induced in  the mesenchy-
mal NMuMG  clones, which would make boundary determination
difficult using the markers we  had chosen (E-cadherin and colla-
gen). After removal of the inserts in which the 2 cell types were
allowed to attach overnight, they were cultured for a further 3 d.
Treatment with TGF1 induced a  clear transgression of 3T3 cells
into the epithelial zone following boundary formation (Fig. 6).
The activation of fibroblasts was also evident in  the mesenchymal
compartment, where cellular elongation and increased collagen
expression were evident. In  contrast, IGFBP-5 induced a more
rounded phenotype to  the mesenchymal cells and, although they
were making abundant collagen, the boundary remained intact.
When administered with TGF1, IGFBP-5 was again able to inhibit
the activation of fibroblasts induced by  TGF1 and thereby prevent
disruption of the boundary between the epithelial and mesenchy-
mal  cells.
In  order to  begin to  assess the relevance of these findings
to  metastasis, we undertook immunohistochemical studies to
determine IGFBP-5 expression in breast cancer biopsy tissue
microarrays. IGFBP-5 expression was  examined in  the nucleus,
cytoplasm and plasma membrane individually. Whilst no relation-
ships were evident for IGFBP-5 expression in the plasma membrane
or cytoplasm, high IGFBP-5 expression in the nucleus was asso-
ciated with increased disease-free intervals when compared to
those with low IGFBP-5 nuclear expression (p = 0.004, 93  vs 83
months respectively). In particular, high expression of IGFBP-5
was associated with significant increases in  disease-free periods
in patients who subsequently received chemotherapy (p =  0.031,
87 vs 77 months), but not in  those who  did not  (Fig. 7). Addition-
ally, this relationship between disease-free survival and expression
of IGFBP-5 was  evident in  patients with high levels of apoptosis
(p =  0.002, 84 vs 100 months in  low and high IGFBP-5 expressers
respectively) but not  in those with low levels of apoptosis.
3. Discussion
NMuMG  cells are  able to form luminal, polarised structures sim-
ilar to the normal mammary alveolar structure, (Swamydas et al.,
2010). Our studies confirmed previous findings (Maeda et al., 2005)
that NMuMG  cells can be separated into stable clones with either
epithelial or mesenchymal characteristics. We now demonstrate,
for the first time, the responses of the mesenchymal clones to  var-
ious growth factors. We generated three independent clones for
both epithelial and mesenchymal cells with almost identical char-
acteristics for clones of the same cell type (although there are subtle
differences, for example in  the number of epithelial cells killed by
TGF1). Both epithelial and mesenchymal cells are stable in pas-
sage for more than 12 months and we believe that they represent
a valuable and novel tool for comparing both EMT  and MET  in the
same cell line.
3.1. IGFBP-5 and epithelial cell adhesion and survival
We recently identified a novel role for IGFBP-5 in  the induc-
tion of epithelial cell adhesion and spreading which could  play an
important part in  the prevention of metastasis and/or limit fibrosis
(Sureshbabu et al., 2012). In this study, we now also demonstrate
this effect in a  normal mouse mammary gland epithelial cell, as
well as describing the ability of IGFBP-5 to antagonise the dis-
ruptive actions of TGF1. The adhesion of epithelial cells induced
by IGFBP-5 was particularly evident in the presence of  collagen
or fibronectin, components of the mesenchymal matrix but was
smaller in magnitude in  the presence of laminin, the major com-
ponent of the epithelial basement membrane. Thus, this action of
IGFBP-5 would be exaggerated during exposure of epithelial cells
bright field conditions. Bar represents 100 m.  Panel D: Quantification of spheroid numbers and size from experiment described in Panel C. Spheroids were classified as having
a  minimum diameter of 25 m (typically 8–10 cells). Values are means ± SEM of 4  observations. *p < 0.05, ***p <  0.001 compared with control. Data for TGF1  are not  shown
as  no spheroids were evident. Panel E: IGFBP-5 antagonises the apoptotic effect of TGF1  on  epithelial cells. Epithelial cells were infected with either adenovirus expressing
IGFBP-5  or the null vector and cultured for 24 h to  allow expression of IGFBP-5 to  be established. Cells were then trypsinised and 4 ×  105 epithelial cells were seeded into
96-well plates in DMEM containing 10% serum. After overnight culture to  allow attachment, and to permit IGFBP-5 secretion to become established, TGF1 (0.1–3 ng/ml)
was  added to the wells. After 3 d  the cells were fixed and stained with crystal violet and absorbances determined at  540 nm. Values are means ± SEM. *p <  0.01 compared with
TGF1  alone. Panel F: IGFBP-5 reduces the epithelial–mesenchymal rearrangement induced by TGF1 in epithelial cells. Epithelial cells were infected with either adenovirus
expressing  IGFBP-5 or the null  vector and cultured for 24  h  to allow expression of IGFBP-5 to be established. Cells were then trypsinised and 4  ×  105 epithelial cells were
seeded  into chamber slides in DMEM containing 10% serum. After overnight culture to allow attachment, and to permit IGFBP-5 secretion to  become established, TGF1
(0.1–3 ng/ml) was added to the wells. After 3 d  the cells were fixed and stained with phalloidin to reveal actin filaments in red (upper panel) or with anti-E-cadherin in green
(lower  panel). Nuclei were stained blue with DAPI. Bar represents 25  m. Panel G: Treatment with IGFBP-5 decreases adhesion of NMuMG  mesenchymal cells. Mesenchymal
cells  (in 0.1% BSA DMEM)  were seeded into 96-well plates coated with laminin, fibronectin or collagen. After 30 min  culture at  37 ◦C, the plates were inverted rinsed and fixed
in  4% paraformaldehyde. They were then stained with crystal violet, photographed and absorbances determined at 540 nm. Panel H:  Quantification of the results of the study
shown  in Panel G. Values are  means ± SEM of 6 observations. ***p  <  0.001 compared with control cells (ANOVA followed by Bonferroni’s test for multiple comparisons). Panel
I:  TGF1 induces activation of mesenchymal cells whereas IGFBP-5 induces de-adhesion, an  action which overrides the  effect of TGF1. TGF1 induces a dose-dependent
activation  of mesenchymal cells,  seen as cell elongation and swirling patterns. IGFBP-5 induces a  dose-dependent de-adhesion and formation of cell clumps (arrows). Panel
J:  When TGF1 and IGFBP-5 were administered together, the effect of IGFBP-5 predominated. (For interpretation of the references to color in figure legend, the reader is
referred  to the web  version of the article.)
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Fig. 4. Panel A: IGFBP-5 induces the formation of epithelial spheroids and its actions are unaffected by various kinase inhibitors. NMuMG epithelial cells were trypsinised and
seeded  into 96-well plates at  4  ×  105 cells/ml in 0.1% BSA DMEM along with various kinase inhibitors (see Section 4 for concentrations) with or without IGFBP-5 (10 g/ml).
Control wells received equivalent concentrations of DMSO. After 24 h culture at 37 ◦C, cells were photographed under bright-field conditions. Panel B:  TGF1  induces
epithelial cell death and its actions are prevented by inhibitors of the Smad pathway. NMuMG  epithelial cells were trypsinised and seeded into 96-well plates at 4 ×  105
cells/ml in DMEM containing 10% serum along with various kinase inhibitors (see Section 4  for concentrations) with or without TGF1  (10 ng/ml). Control wells received
equivalent concentrations of DMSO. After 24 h  culture at 37 ◦C, cells were fixed, stained with crystal violet and absorbances determined at 540 nm. Values are  means ± SEM of
6  observations. ***p <  0.001 compared with respective control wells (ANOVA followed by Bonferroni’s test for multiple comparisons). Panel C: TGF1 increases phosphoryla-
tion  of Smad 2/3 in epithelial cells, whereas IGFBP-5 has no effect. NMuMG epithelial cells were seeded into 12-well plates overnight. They were then washed and treated with
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Fig. 5. IGFBP-5 enhances wound closure in NMuMG  epithelial cells but inhibits it in  NMuMG mesenchymal cells, thereby antagonising the actions of TGF1.  Panel A: Epithelial
cells  were seeded into ibidi 2-chamber inserts to  produce confluent monolayers overnight. The inserts were then removed and the cells cultured in DMEM containing 10%
serum with or without TGF1 (2 ng/ml) or IGFBP-5 (10 g/ml) or a combination of both. Migration was allowed to  proceed for 24 h and the cells were then fixed, stained with
crystal violet and photographed. Bar represents 250 m.  Panel B: Mesenchymal cells were seeded into ibidi 2-chamber inserts to produce confluent monolayers overnight.
The  inserts were then removed and the cells cultured in DMEM containing 10%  serum with or without TGF1 (2 ng/ml) or IGFBP-5 (10  g/ml) or a combination of both.
Migration was allowed to proceed for 24  h and the cells were then fixed, stained with crystal violet and photographed. Bar represents 250 m.  Panels C and D: Quantitative
analysis of the studies described in panels A and B, respectively. Values are means ± SEM of 6–8 observations. *p < 0.05, ***p <  0.001 compared with control. ap < 0.01 compared
with  TGF1 alone.
to a mesenchymal environment, such as occurs during the tissue
disruption evident in  wound-healing or metastasis. Similar alter-
ations in the response of both IGFBP-3 and IGFBP-5 in  the presence
of laminin or fibronectin have been described previously (McCaig
et al., 2002; Sureshbabu et al., 2012).
Although IGFBP-5 significantly extended epithelial cell survival,
initially by driving cell adhesion to the substratum, it ultimately
induced the formation of spheroids where, presumably, the forces
involved in cell–cell contact were stronger than the cell-substratum
interaction and thus became the major determinant of pheno-
type. This response of the epithelial cells was similar to the effect
of IGFBP-5 in MCF-7 breast cancer cells, where IGFBP-5 induced
adhesion to the substratum. and maintained E-cadherin expres-
sion and strong cell–cell contact (Sureshbabu et al., 2012). What
role might this response play? IGFBP-5 expression is  increased
in the brain during hypoxia (O’Donnell et al., 2002)  in Crohn’s
disease (Zimmermann et al., 1997)  in  atherosclerotic plaques
and in senescing cells (Kim et al., 2007). Survival in nutrient-
deprived/oxygen-depleted conditions is advantageous for tissue
repair after injury, when vasculature is compromised and hypoxia
is common and thus IGFBP-5 may  play an important role in  aiding
epithelial cell survival and repair at these times (Johnson and Haun,
2009; Sureshbabu et al., 2012).
TGF1,  in complete contrast to IGFBP-5, induced apoptosis
of >80% of cells and induced EMT  in  the remaining cells, as
evidenced by the complete loss of E-cadherin expression and the
re-organisation of actin into stress fibres, confirming previous find-
ings (Maeda et al., 2005). Furthermore, when epithelial clones were
treated with TGF1  in the presence of IGFBP-5 both the apoptotic
and EMT  effects of TGF1 were considerably reduced, though not
ablated. Such antagonism of TGF1 actions would again support a
pro-survival action of IGFBP-5 in  the epithelium.
3.2. Effects of IGFBP-5 on adhesion and survival of mesenchymal
cells
When the actions of IGFBP-5 were examined on mesenchy-
mal  NMuMG  cells or classical 3T3 fibroblasts, IGFBP-5 induced a
striking inhibition of their adhesion to  the substratum, in  com-
plete contrast to its effects upon epithelial cells. However, this lack
of adhesion was somewhat artefactual, since the cells began to
form small spheroids, apparently demonstrating a preference for
TGF1 with or without IGFBP-5 for 30 min. Cells were harvested and subjected to  Western blotting for phospho- Smad 2/3. Representative blots are shown on the left  and
quantitative analysis using Image J  is  shown on the right. M,  molecular weight markers; C, control; T, TGF1; I,  IGFBP-5. Values are means ± SEM of 5  observations. **p <  0.01
compared with control cells. Panel D: IGFBP-5 induces de-adhesion of NMuMG mesenchymal cells and is  unaffected by various kinase inhibitors. NMuMG mesenchymal cells
were  trypsinised and seeded into 96-well plates at 4 ×  105 cells/ml in 0.1% BSA  DMEM along with various kinase inhibitors (see Section 4 for concentrations) with or without
IGFBP-5  (10 g/ml). Control wells received equivalent concentrations of DMSO. After 24 h  culture at 37 ◦C, cells were fixed, stained with crystal violet, photographed and
absorbances determined at 540 nm. Panel E: Quantitative analysis of data derived from the study shown in Panel D. Values are means ± SEM of 6 observations. ***p  < 0.001
compared with respective control wells (ANOVA followed by Bonferroni’s test for multiple comparisons).
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Fig. 6. TGF1 induced mesenchymal cell invasion of the  epithelial cell layer: inhibition by  IGFBP-5. NMuMG  epithelial cells were infected with IGFBP-5 adenovirus or null
adenovirus and after overnight culture, the cells were trypsinised and 3 × 104 cells were seeded into one chamber of an  ibidi 2  chamber insert in a  24-well tissue culture
plate.  2 × 104 3T3 cells were seeded into the opposite chamber. After overnight culture, to  allow adhesion, the inserts were removed and the  cells cultured for a  further 3  d
in  the presence or absence of TGF1 (2 ng/ml). Cells were then fixed and stained for E-cadherin (red) or collagen (green). Bar represents 100 m. (For interpretation of the
references to color in figure legend, the reader is referred to the web  version of the article.)
cell–cell contact rather than cell substratum interactions (similar
to that observed in the epithelial clones). This could be  interpreted
as a more epithelial characteristic, suggestive of an induction of
MET. Whilst we would have liked to  investigate this possibility
by, for example, examining E-cadherin expression in these mes-
enchymal clones this proved impossible because the poor adhesion
of the spheroids to the substratum meant that any immunohis-
tochemical approach (involving multiple washes) resulted in  the
loss of all of the spheroids. Once again however, these actions
of IGFBP-5 were in complete contrast to  those of TGF1 and,
importantly, IGFBP-5 was able to completely antagonise the actions
of TGF1 on mesenchymal cells when they were administered
together.
3.3. Effects of IGFBP-5 on wound closure
IGFBP-5 enhanced epithelial cell wound closure, whereas
TGF1 induced the opposite effect and, when administered in
combination, IGFBP-5 was  able to  partially inhibit this action of
TGF1. In mesenchymal cells (both NMuMG cells and 3T3 cells)
Fig. 7. High expression of IGFBP-5 increase disease-free intervals in patients receiving chemotherapy or with high TUNEL expression. Kaplan–Meier survival plots showing
the  effect of expression of nuclear IGFBP-5 on  recurrence of breast cancer in patients who  did or did not  receive chemotherapy and in patients with high or low  TUNEL
expression.
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the opposite was  evident, where TGF1 increased wound closure,
whereas IGFBP-5 antagonised this effect.
Taken together, these results suggest that IGFBP-5 can inhibit
the pro-fibrotic/pro-metastatic actions of TGF1, both in terms
of the effects of TGF1 on epithelial cells (pro-apoptotic, induc-
tion of EMT) and mesenchymal cells (pro-adhesion, pro-migratory).
However, there is undoubtedly a  pro-fibrotic response to IGFBP-
5, based upon a  number of published studies (Pilewski et al.,
2005; Yasuoka et al., 2006a, 2006b). So, how might these appar-
ently contradictory findings be reconciled? We  believe our studies
on epithelial–mesenchymal boundaries shed some light on this.
IGFBP-5 clearly inhibited the disruptive effects of TGF1 on the
maintenance of epithelial–mesenchymal boundaries. IGFBP-5 has
also been shown to increase the production of laminin-1 a  major
constituent of the epithelial basement membrane which aids in
re-enforcement of the boundary (Abrass and Hansen, 2010).  If we
take into account the fact that  IGFBP-5 is expressed in a num-
ber of tissues during injury or remodelling such as hypoxia in
the brain, atherosclerotic plaques and involution of the mammary
gland (Tonner et al., 2002), then it is  conceivable that IGFBP-5 pro-
duced by injured/dying epithelial cells, induces spreading/adhesion
of neighbouring cells to provisional matrices or mesenchymal envi-
ronments (to which they would not normally be exposed). This
would allow more effective maintenance/repair of the epithelial
barrier. At the same time, by promoting collagen and fibronectin
production in the mesenchymal compartment, IGFBP-5 would sup-
port a “back-up” scar tissue response which would be present until
epithelial repair was achieved. IGFBP-5 would, therefore, be able
to support a controlled fibrotic response, rather than the massive
and typically unresolved fibrotic scarring evident when TGF1  is
active. Thus, although IGFBP-5 is  up-regulated in fibrosis (Feghali
and Wright, 1999), this may  reflect a  positive repair strategy by
epithelial tissues.
Precisely how IGFBP-5 acts remains uncertain. Our studies
were almost exclusively done in  the absence of exogenous IGF-I,
although we cannot rule out endogenous production of IGFs by the
cells. However, our studies in  MCF-7 cells included the use of a
mutant form of IGFBP-5 which could not bind to IGFs (Allan et al.,
2006) and this was fully active in  inducing adhesion and inhibiting
migration (Sureshbabu et al., 2012) suggesting that the actions of
IGFBP-5 are indeed IGF-independent. We found no evidence that
IGFBP-5 could inhibit the actions of TGF1 on its receptor or imme-
diate downstream signal via Smad2/3. These results are consistent
with a previous study which showed that IGFBP-3 but not IGFBP-5
could influence Smad signalling (Fanayan et al., 2002). Our previous
study identified a  novel interaction of IGFBP-5 with 21 integrins
which was required for adhesion and an Akt-induced survival path-
way  (via integrin- rather than via PI-3 kinase). The fact that  none of
the classical signalling pathways appeared to  have a  major role in
the adhesive action of IGFBP-5 is consistent with our previous find-
ings, although it  is at odds with the activation of MAPK by IGFBP-5
along with stimulation of collagen and fibronectin production in
another study (Yasuoka et al., 2009). However, the induction of
fibronectin and collagen production by IGFBP-5 supports, rather
than inhibits, the actions of TGF1 and this suggests that IGFBP-5
functions in at least 2 ways in  mesenchymal cells. This mechanism
of action resembles that of members of the CCNs, a family of pro-
teins structurally-related to IGFBP-5, which involves interactions of
integrins with the extracellular matrix (Leask and Abraham, 2006).
3.4. IGFBP-5 and cancer
So what of the associations of IGFBP-5 with cancer? Early studies
identified increased IGFBP-5 expression in  tumours and led to the
proposal that IGFBP-5 was pro-metastatic (Hou et al., 2009; Huynh,
1998; McGuire et al., 1994; Mita et al., 2007; Pekonen et al., 1992).
However, our data, along with other recent reports, suggest that
IGFBP-5 is protective. For example, IGFBP-5 expression has recently
been shown to  be associated with increased survival times in  breast
cancer patients as well as being responsible for maintaining sensi-
tivity to  tamoxifen (Ahn et al., 2010).  In addition, overexpression
of IGFBP-5 in MCF-7 xenografts inhibited tumour development in
mice (Ahn et al., 2010) whilst recent studies have demonstrated
a tumour suppressor role for IGFBP-5 in ovarian cancer cells (Rho
et al., 2008) in osteosarcoma (Su et al., 2011) and in breast cancer
after foetal alcohol exposure (Polanco et al., 2010).  An intrigu-
ing relationship between IGFBP-5 and tumour dormancy has also
been described. Genome-wide transcriptional analysis identified a
small cohort of genes, of which IGFBP-5 was one, which were up-
regulated in  dormant tumours of breast carcinoma, glioblastoma,
osteosarcoma, and liposarcoma (Almog et al., 2009; Satchi-Fainaro
et al., 2012).  Our own  observations of increased time to recurrence
of breast cancer in individuals with high expression of IGFBP-5 add
further weight to an anti-metastatic role for IGFBP-5. The fact that
the relationship was evident for nuclear expression of IGFBP-5 is
intriguing as IGFBP-5 has a  nuclear localisation signal and nuclear
actions of IGFBP-5 have been described. Although these remain the
subject of debate (Jurgeit et al., 2007) this intra-nuclear role has
been reported to be pro-apoptotic (Lee et al., 2004)  and thus may be
another mechanism by which IGFBP-5 increases survival of breast
cancer patients. Why the role of IGFBP-5 should be  most evident in
those patients who  undergo chemotherapy compared with those
who do not, also requires explanation. For example, is the action of
IGFBP-5 more effective in  more aggressive tumours, those which
typically require chemotherapy?
In summary, IGFBP-5 plays an important role in the epithelial
cell response to injury/insult by inducing adhesion of epithelial cells
to  the provisional matrix and enhancing epithelial wound closure,
in order to  maximise the efficiency of barrier repair. At  the same
time, IGFBP-5 enhances deposition of scar tissue by mesenchymal
cells but prevents their transgression into the epithelial compart-
ment, partly by re-enforcement of the epithelial barrier and partly
by inducing an MET-like response and decreasing migration poten-
tial of mesenchymal cells. As such IGFBP-5 may  be an important
regulator of the pro-fibrotic and pro-metastatic actions of TGF1
and could thus offer alternative routes to  the generation of  anti-
fibrotic and anti-metastatic agents.
4. Materials and methods
4.1. Production of recombinant IGFBP-5
Wild type IGFBP-5 was produced as described previously (Allan
et al., 2002; Shand et al., 2003).
4.2. Generation of adenovirus containing IGFBP-5
This was performed exactly as described previously
(Sureshbabu et al., 2012)
4.3. Cell culture
NMuMG  cells, a mouse mammary epithelial cell line, were
obtained from ECACC (Cat No: 94081121). They were cultured in
DMEM supplemented with 2 mM glutamine, penicillin (5.0 U/ml)
streptomycin (5 mg/ml) insulin (10 g/ml) and 10% foetal bovine
serum. Insulin was omitted from the medium for all experiments
in  which a  response to  IGF-I was to be  determined.
NIH 3T3 cells (ATCC no: CRL-1658) were cultured in DMEM with
2 mM glutamine, penicillin (5.0 U/ml), streptomycin (5 mg/ml), and
10% FBS.
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4.4.  Establishment of NMuMG  clones
The NMuMG  clones were established by limiting dilution of the
original parent population of NMuMG  cells. Generating two distinct
cell types, one (epithelial) in which cell:cell adhesion was strong
another (mesenchymal), where the cells showed little interaction.
4.5. Determination of optimum concentrations for  adenoviral
infection of cells
Replication-deficient adenovirus containing the IGFBP-5 gene
was used to infect NMuMG  cells with a  null adenovirus serving as
a negative control.
After trypsinisation, NMuMG  cells were washed in  serum-free
DMEM.  The cells were then infected with adenovirus in the wells of
a 6-well tissue culture plate pre-coated with 1 g/ml of collagen to
support the adhesion of the NMuMG  cells in the absence of serum.
Plates were cultured for 3 h,  followed by supplementation with 10%
FCS (to aid survival), followed by overnight incubation. The fol-
lowing day the cells were trypsinised, washed, counted and added
to 24-well plates and cultured at 37 C in 95% air/5% CO2.  Medium
from the wells was collected every day, for the determination of
the IGFBP-5 concentration by  enzyme linked immunosorbent assay
(ELISA) to determine appropriate infection levels.
4.6. Enzyme linked immunosorbent assay (ELISA)
ELISA (IGFBP-5 Mouse ELISA Kit, a100693,) was performed to
determine the concentration of the IGFBP-5 produced from the
adenoviral infected NMuMG  cells exactly according to  the man-
ufacturer’s instructions (Abcam, Cambridge UK).
4.7. Cell adhesion
Various concentrations of IGFBP-5, TGF1,  IGF-I and insulin
were prepared in  0.1% BSA: DMEM.  The treatments (as described in
Section 2) were added to  96 well plates. 3 × 104 NMuMG  epithelial
clones, mesenchymal clones or 3T3 cells, also in 0.1% BSA: DMEM,
were added to triplicate wells. Plates were then cultured for either
30 min  or overnight at 37 ◦C in  a 5% CO2 atmosphere. The cells were
then photographed, after which the medium was  removed and cells
were fixed with 100 l  of 4%  (w/v) paraformaldehyde in phosphate
buffer saline (PBS) for 20 min  at room temperature, After staining
with crystal violet, and washing, the absorbance was  determined
at 540 nm.
4.8. Cell signalling studies: Inhibition assays
To  examine the possible intracellular signalling pathways of
IGFBP-5 and TGF1,  various kinase inhibitors were added to 96-
well plates containing 3 ×  104 cells in DMEM containing 10% serum,
in the presence or  absence of IGFBP-5 or TGF1 and cultured for
24 h, after which cells were fixed and stained with crystal vio-
let. Final concentrations of the inhibitors used were LY-294,002
(5 M),  PD98,059 (25 M),  SB203,580 (1 M)  UO126 (10 M)
A83.01 (10 M) and SB431542 (10 M).  Control wells contained
an equivalent concentration of DMSO.
4.9. WST-1 assay
To determine metabolic activities, at the end of the culture
period, WST-1 reagent (5 l/well) was added to 96-well plates and
culture continued for 1 h before the absorbance was read at 450 nm.
4.10. Western immunoblotting
NMuMG  cells grown to  80% confluency on 12 well plates were
treated with either TGF-1 (10 ng/ml) alone, IGFBP-5 (10 g/ml)
alone or TGF-1 plus IGFBP-5 for 30 min  before harvesting. Cells
were harvested in sample buffer containing (125 mM  Tris-Base (pH
6.7), 0.5 mM  Na4P2O7,  1.25 mM EDTA, 1.25% (v/v) glycerol, 0.5%
(w/v) SDS, 25 mM 1,4-dithiothreitol (DTT) and 0.02% (w/v) bro-
mophenol blue) and were subjected to SDS-PAGE and Western
blotting as previously described (Alderton et al., 2001). Resolved
proteins were Western blotted with anti-phospho-smad 2 (Cell
signalling, code 3108P)and visualised using the enhanced chemi-
luminescence method.
4.11. Immunofluorescence staining
Cells were cultured in  8-well chamber slides. At  the end of the
culture period, medium was removed from the wells by inverting
the chamber slides and cells were fixed with 200 l of 2% (w/v)
paraformaldehyde in  PBS for 10 min  followed by permeabilization
with 200 l  of 0.5% triton X-100 in PBS for 15 min  at room tem-
perature. Non-specific staining was diminished by incubating with
10% heat-inactivated serum, derived from the species in which the
second antibody was produced. Cells were incubated with 200 l
of mouse anti-E-cadherin (5 g/ml) (Invitrogen, Cat no: 334000)
anti-collagen (1:500) (Abcam, Cat .No: ab88147) or anti-fibronectin
(1:500) (Abcam, Cat No: ab23750). This was  followed by 1  h incu-
bation with secondary antibody labelled with either Texas red or
FITC (1:200). F-actin was detected using either rhodamine- or  FITC-
phalloidin (Biotium, USA). Slides were covered with antifade DAPI
nucleic acid mountant (Molecular Probes, Invitrogen, USA). The
slides were visualised with a Nikon TE300 (Nikon, Kingston upon
Thames, UK) inverted epifluorescence microscope using ×40  or
×100 objectives with oil immersion and a  Hamamatsu CCD cam-
era (Hamamatsu Photonics, Welwyn Garden City, UK) controlled
by Metamorph software (Molecular Devices, Palo Alto, CA, USA)
or a Leica DMIRB microscope (Leica Microsystems (UK) Ltd Milton
Keynes, Bucks, UK) using a  ×40 objective (Leica N PLAN 40×/0.55
NA CORR PH2 0–2/C) a  ×10 objective (Leica N PLAN 10×/0.25 PH1
-/A  5.8) or a  ×5  objective (Leica N PLAN 5×/0.12 PH0 -/A). Images
were captured on a  Leica DC200 (DMIRB) and analysed using a Leica
Q550 Image Analysis Workstation (v2.2.1) combined with Leica
Qwin Software for image acquisition.
The images were optimised using Adobe Photoshop. Composite
pictures were taken and adjustments in brightness and contrast
were applied equally across all images to prevent the introduction
of any bias.
4.12.  Migration assays
The cell migration assay was  carried out in  24-well plates using
ibidi 2-chamber inserts (Thistle Scientific Ltd, Glasgow). Cham-
bers were added to the wells and then seeded with, typically
30,000–50,000 cells to achieve a  confluent monolayer overnight.
Treatments were also added at this time. After overnight culture
the inserts were removed to reveal 2 patches of cells separated
by a  500 m gap. Fresh medium containing treatments was  added
and migration allowed to proceed until stopped by fixing in  4% PFA.
Cells were stained with crystal violet and images taken for analysis
using ImageJ software.
4.13. Boundary assays
Boundary assays utilised the same ibidi chambers but each
chamber received different cells (epithelial in one and mesenchy-
mal  in the other). After overnight culture the inserts were removed
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and the culture continued for a  further 24 h to allow boundary
formation to occur. Exogenous treatments were then added and
cells  cultured for a further 48 h, after which they were fixed and
stained for E-cadherin (epithelial marker and collagen (mesenchy-
mal  marker).
4.14. Patients and tissue microarray (TMA) construction
A total of 371 patients were included in this study, all presenting
with invasive breast cancer between 1995 and 1998 and recruited
in the Greater Glasgow area. Available clinico-pathological data for
each patient included age, tumour grade, tumour invasive grade,
lymph node status, oestrogen receptor (ER) status, HER2 status and
what therapy the patient had received. The data was retrieved from
the NHS electronic patient notes by  a member of the health care
team as this was a  retrospective study. Recurrence was  determined
when the patients returned to clinic with symptoms and recur-
rence was evident, or on a  routine follow-up appointment when a
recurrence was identified.
TMAs were already available for use in this study. These were
constructed using 0.6 mm2 cancer tissue cores taken from rep-
resentative areas of tumour from each patient. All blocks were
constructed in triplicate containing three individual tumour cores
taken from the same embedded tissue sample.
4.15. Immunohistochemistry
Immunohistochemistry was used to assess protein expression
in the tissue. TMAs were rehydrated in graded alcohols followed
by heat induced antigen retrieval in  EDTA buffer pH9 for 5 min  in
a pressure cooker. Endogenous peroxidase was quenched with 3%
hydrogen peroxide for 20 min  and non-specific binding of primary
antibody was blocked by incubation of TMAs in  5%  horse serum
in  1× Tris-buffered saline (TBS) for 30 min. Tissue was then incu-
bated in 5 g/ml IGFBP5 mouse monoclonal antibody (MAB875,
R&D systems, USA) overnight at 4 ◦C.  Slides were incubated in Dako
EnVisionTM secondary antibody (Dako, Denmark) for 30 min  and
staining was detected using the chromogen 3,3′-diaminobenzidine
(DAB) for 5 min. Tissue was then counterstained with haemo-
toxylin, dehydrated in graded alcohols and xylene and mounted
with glass coverslips using DPX.
4.16. Scoring
Protein expression was assessed using the weighted histoscore
method (Kirkegaard et al., 2006). This method first grades the inten-
sity of staining from 0 (negative) to  3 (strong) and then multiplies
the grade by the percentage of tumour cells within each category.
The final histoscore varies between 0 (minimum) and 300 (maxi-
mum)  and is averaged for the triplicate samples.
Statistical analysis was  performed using SPSS version 19.0
for Windows. Univariate outcome analyses were conducted by
Kaplan–Meier methods, using the log-rank test to  compare out-
come between patients grouped according to clinico-pathologic
parameters and high/low protein expression. Disease-free survival
rates were obtained using Kaplan–Meier method. The log-rank test
was used to compare survival curves between subgroups.
4.17. Patient approval
Ethical approval was gained from the local ethics committee.
Due to the retrospective nature of the study patient consent was
not required.
4.18. Statistical analysis
In vitro study data were analysed using Analysis of  Variance
followed by Bonferroni’s post hoc test.
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